Arm Enters Legal Crosshairs as Qualcomm Takes Stand in Delaware Licensing Trial

A new chapter in Arm Holdings’ longstanding licensing disputes unfolded as Qualcomm renewed legal action, reopening trial proceedings in Delaware on October 5, 2026. Qualcomm alleges Arm withheld critical chip-testing tools and publicly disclosed a threat to terminate a vital architecture license—a disclosure Qualcomm says hindered its negotiations with Meta Platforms. The outcome could affect billions in royalty payments. Arm stock (ticker ARM) currently trades at USD 255.24, down 1.94% as of October 12, 2026.

Qualcomm Seeks to Suspend Royalties in High-Stakes Licensing Battle

Qualcomm’s lawsuit, which entered a five-day trial beginning October 5, centers on claims that Arm failed to deliver technology required under their Architecture License Agreement and leaked a termination warning to the media—actions Qualcomm contends damaged its deal discussions with Meta Platforms. The chipmaker is seeking to suspend royalty payments to Arm for up to five years, a remedy that could amount to billions of dollars. Arm denies any breach of contract. This trial has important implications for one of Arm’s largest customers and its royalty revenue stream.

The broader licensing agreement remains in effect through 2033, but this trial could significantly impact Arm’s financial flows depending on the verdict. The judge is weighing whether Qualcomm’s requested remedy is legally enforceable.

Arm’s Business Momentum Meets Legal Uncertainty

Arm’s financial foundation remains strong. In its first quarter of fiscal year 2027, the company reported record-setting results, with total revenue of USD 1.29 billion—up 22% year-over-year—driven by licensing and royalty strength. Licensing revenue surged 23% to USD 574 million, while royalty collections grew 22% to USD 715 million. Arm also highlighted that demand for its Arm AGI CPU product had grown sharply, with a pipeline exceeding USD 2 billion and manufacturing capacity secured to meet an initial USD 1 billion in orders. Neoverse core shipments surpassed 1.5 billion, marking a significant acceleration in deployment. Guidance for Q2 projects revenue of USD 1.38 billion at mid-point, with licensing expected to grow approximately 30% year-over-year and royalty revenue up in the low teens.

Stock Watching: ARM’s Price Reaction Amid Court Drama

Arm’s stock price of USD 255.24 as of October 12, 2026 reflects a 1.94% decline for the day amid market uncertainty linked to the trial. While the company’s strong revenue and licensing trajectory offer significant support, investor sentiment may be constrained by the risk to royalty inflows should Qualcomm prevail in halting payments. At the current price level, the court proceedings present a notable variable for ARM’s near-term stock performance.

What to Watch Next

The trial is ongoing, and no verdict had been delivered as of October 9. The court’s decision—or any settlement—will be a key catalyst for Arm’s financial outlook, especially around royalties. Investors should monitor developments closely, particularly any ruling on Qualcomm’s request to pause royalty payments. Should such a relief be granted, Arm could face material revenue disruption.

Despite legal risks, Arm’s robust licensing momentum, AGI CPU demand, and expanding Neoverse deployments continue to underpin its strategic growth trajectory. The court’s decision will be pivotal in shaping the company’s near-term revenue visibility.

Note: Arm’s stock price and percentage change refer to the verified quote as of October 12, 2026 and have not been altered or updated beyond that date.